Literature DB >> 19129758

Pulmonary fibrosis: pathogenesis, etiology and regulation.

M S Wilson1, T A Wynn.   

Abstract

Pulmonary fibrosis and architectural remodeling of tissues can severely disrupt lung function, often with fatal consequences. The etiology of pulmonary fibrotic diseases is varied, with an array of triggers including allergens, chemicals, radiation and environmental particles. However, the cause of one of the most common pulmonary fibrotic conditions, idiopathic pulmonary fibrosis (IPF), is still unclear. This review examines common mechanisms of pulmonary wound-healing responses following lung injury, and highlights the pathogenesis of some of the most widespread pulmonary fibrotic diseases. A three phase model of wound repair is reviewed that includes; (1) injury; (2) inflammation; and (3) repair. In most pulmonary fibrotic conditions dysregulation at one or more of these phases has been reported. Chronic inflammation can lead to an imbalance in the production of chemokines, cytokines, growth factors, and disrupt cellular recruitment. These changes coupled with excessive pro-fibrotic IL-13 and/or TGFbeta1 production can turn a well-controlled healing response into a pathogenic fibrotic response. Endogenous regulatory mechanisms are discussed including novel areas of therapeutic intervention. Restoring homeostasis to these dysregulated healing responses, or simply neutralizing the key pro-fibrotic mediators may prevent or slow the progression of pulmonary fibrosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19129758      PMCID: PMC2675823          DOI: 10.1038/mi.2008.85

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  373 in total

1.  Inflammation in idiopathic pulmonary fibrosis.

Authors:  Pierre F Piguet
Journal:  Am J Respir Crit Care Med       Date:  2003-04-01       Impact factor: 21.405

2.  Expression of the immunomodulator IL-10 in type I pneumocytes of the rat: alterations of IL-10 expression in radiation-induced lung damage.

Authors:  Michael G Haase; Anke Klawitter; Peter Geyer; Gustavo B Baretton
Journal:  J Histochem Cytochem       Date:  2007-08-06       Impact factor: 2.479

Review 3.  Efficacy and safety of aerosolized tobramycin in cystic fibrosis.

Authors:  V B Pai; M C Nahata
Journal:  Pediatr Pulmonol       Date:  2001-10

4.  The CC chemokine eotaxin/CCL11 has a selective profibrogenic effect on human lung fibroblasts.

Authors:  Ilaria Puxeddu; Reem Bader; Adrian Martin Piliponsky; Reuven Reich; Francesca Levi-Schaffer; Neville Berkman
Journal:  J Allergy Clin Immunol       Date:  2005-12-02       Impact factor: 10.793

5.  Mechanisms of neutrophil accumulation in the lungs of patients with idiopathic pulmonary fibrosis.

Authors:  G W Hunninghake; J E Gadek; T J Lawley; R G Crystal
Journal:  J Clin Invest       Date:  1981-07       Impact factor: 14.808

6.  MMP expression and abnormal lung permeability are important determinants of outcome in IPF.

Authors:  S McKeown; A G Richter; C O'Kane; D F McAuley; D R Thickett
Journal:  Eur Respir J       Date:  2008-10-01       Impact factor: 16.671

7.  Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain.

Authors:  Thirumalai R Ramalingam; John T Pesce; Faruk Sheikh; Allen W Cheever; Margaret M Mentink-Kane; Mark S Wilson; Sean Stevens; David M Valenzuela; Andrew J Murphy; George D Yancopoulos; Joseph F Urban; Raymond P Donnelly; Thomas A Wynn
Journal:  Nat Immunol       Date:  2007-12-09       Impact factor: 25.606

8.  Complex regulation of pulmonary inflammation and fibrosis by CCL18.

Authors:  Kerill Pochetuhen; Irina G Luzina; Virginia Lockatell; Jung Choi; Nevins W Todd; Sergei P Atamas
Journal:  Am J Pathol       Date:  2007-06-14       Impact factor: 4.307

9.  Microbiology of early CF lung disease.

Authors:  Lisa Saiman
Journal:  Paediatr Respir Rev       Date:  2004       Impact factor: 2.726

10.  Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract.

Authors:  Alexander M Owyang; Colby Zaph; Emma H Wilson; Katherine J Guild; Terrill McClanahan; Hugh R P Miller; Daniel J Cua; Michael Goldschmidt; Christopher A Hunter; Robert A Kastelein; David Artis
Journal:  J Exp Med       Date:  2006-04-10       Impact factor: 14.307

View more
  264 in total

1.  Repetitive intradermal bleomycin injections evoke T-helper cell 2 cytokine-driven pulmonary fibrosis.

Authors:  Brijendra Singh; Rajesh K Kasam; Vishwaraj Sontake; Thomas A Wynn; Satish K Madala
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-03       Impact factor: 5.464

2.  Thiol-redox antioxidants protect against lung vascular endothelial cytoskeletal alterations caused by pulmonary fibrosis inducer, bleomycin: comparison between classical thiol-protectant, N-acetyl-L-cysteine, and novel thiol antioxidant, N,N'-bis-2-mercaptoethyl isophthalamide.

Authors:  Rishi B Patel; Sainath R Kotha; Lynn A Sauers; Smitha Malireddy; Travis O Gurney; Niladri N Gupta; Terry S Elton; Ulysses J Magalang; Clay B Marsh; Boyd E Haley; Narasimham L Parinandi
Journal:  Toxicol Mech Methods       Date:  2012-06       Impact factor: 2.987

3.  Modulation of lung inflammation by the Epstein-Barr virus protein Zta.

Authors:  James F Guenther; Jennifer E Cameron; Hong T Nguyen; Yu Wang; Deborah E Sullivan; Bin Shan; Joseph A Lasky; Erik K Flemington; Gilbert F Morris
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-09-03       Impact factor: 5.464

4.  MyD88 signaling pathway is involved in renal fibrosis by favoring a TH2 immune response and activating alternative M2 macrophages.

Authors:  Tarcio Teodoro Braga; Matheus Correa-Costa; Yuri Felipe Souza Guise; Angela Castoldi; Cassiano Donizetti de Oliveira; Meire Ioshie Hyane; Marcos Antonio Cenedeze; Simone Aparecida Teixeira; Marcelo Nicolas Muscara; Katia Regina Perez; Iolanda Midea Cuccovia; Alvaro Pacheco-Silva; Giselle Martins Gonçalves; Niels Olsen Saraiva Camara
Journal:  Mol Med       Date:  2012-10-24       Impact factor: 6.354

5.  A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model.

Authors:  J S Swaney; C Chapman; L D Correa; K J Stebbins; R A Bundey; P C Prodanovich; P Fagan; C S Baccei; A M Santini; J H Hutchinson; T J Seiders; T A Parr; P Prasit; J F Evans; D S Lorrain
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 6.  MicroRNAs in mucosal inflammation.

Authors:  Viola Neudecker; Xiaoyi Yuan; Jessica L Bowser; Holger K Eltzschig
Journal:  J Mol Med (Berl)       Date:  2017-07-20       Impact factor: 4.599

7.  Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.

Authors:  Lynne A Murray; Huilan Zhang; Sameer R Oak; Ana Lucia Coelho; Athula Herath; Kevin R Flaherty; Joyce Lee; Matt Bell; Darryl A Knight; Fernando J Martinez; Matthew A Sleeman; Erica L Herzog; Cory M Hogaboam
Journal:  Am J Respir Cell Mol Biol       Date:  2014-05       Impact factor: 6.914

8.  Bleomycin delivery by osmotic minipump: similarity to human scleroderma interstitial lung disease.

Authors:  Rebecca Lee; Charles Reese; Michael Bonner; Elena Tourkina; Zoltan Hajdu; Ellen C Riemer; Richard M Silver; Richard P Visconti; Stanley Hoffman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-02-28       Impact factor: 5.464

Review 9.  Matrix remodeling in chronic lung diseases.

Authors:  Bon-Hee Gu; Matthew C Madison; David Corry; Farrah Kheradmand
Journal:  Matrix Biol       Date:  2018-03-17       Impact factor: 11.583

10.  Immunization with recombinant Pb27 protein reduces the levels of pulmonary fibrosis caused by the inflammatory response against Paracoccidioides brasiliensis.

Authors:  Elis Araujo Morais; Estefânia Mara do Nascimento Martins; Jankerle Neves Boelone; Dawidson Assis Gomes; Alfredo Miranda Goes
Journal:  Mycopathologia       Date:  2014-12-09       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.